8-K

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

Date of Report (Date of Earliest Event Reported): March 29, 2024

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

Indiana	001-38661	82-5497352
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2500 Innovation Way Greenfield, Indiana (Address of principal executive offices) 46140 (Zip Code)

Registrant’s telephone number, including area code: (877) 352-6261

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	ELAN	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive Agreement.

On March 29, 2024, Elanco Animal Health Incorporated (the “Company”) entered into a cooperation agreement (the “Cooperation Agreement”) with Ancora Catalyst Institutional, LP and certain of its affiliates (together, the “Ancora Parties”).

Pursuant to the Cooperation Agreement, the Company has appointed Kathy V. Turner and Craig S. Wallace to the Company’s Board of Directors (the “Board”), effective as of March 29, 2024. The Cooperation Agreement provides for customary director replacement procedures in the event either Ms. Turner or Mr. Wallace cease to serve as a director under certain circumstances as specified in the Cooperation Agreement.

Pursuant to the Cooperation Agreement, the Company also agreed to appoint Ms. Turner and Mr. Wallace to the Finance and Oversight Committee of the Company’s Board, which will be renamed the “Finance, Strategy and Oversight Committee.”

Pursuant to the Cooperation Agreement, the Ancora Parties have agreed to abide by certain customary standstill restrictions, voting commitments, and other provisions, such as a mutual non-disparagement provision, which remain in effect until the earlier of (i) the date that is 30 days prior to the deadline for the submission of shareholder nominations for the Company’s 2025 annual meeting of shareholders pursuant to the Company’s Amended and Restated Bylaws or (ii) the date that is 120 days prior to the first anniversary of the Company’s 2024 annual meeting of shareholders.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the Cooperation Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 29, 2024, Ms. Turner and Mr. Wallace were appointed to the Board. Mr. Wallace joined the class with a term expiring in 2025. Ms. Turner joined the class with a term expiring in 2026, with the understanding that Ms. Turner will ultimately be a member of, and be appointed to, the 2025 class in connection with the classes being rebalanced by the Board re-allocating an existing member of the 2025 class to the 2026 class. In connection with the appointments of Ms. Turner and Mr. Wallace, the size of the Board was increased from 12 to 14 members.

Ms. Turner and Mr. Wallace will join the Finance, Strategy and Oversight Committee pursuant to the Cooperation Agreement.

Ms. Turner and Mr. Wallace were appointed to the Board pursuant to understandings with the Ancora Parties, which are shareholders of the Company. The disclosures set forth in Item 1.01 above are incorporated herein by reference.

Except for the Cooperation Agreement described in Item 1.01 above, there were no arrangements or understandings pursuant to which Ms. Turner or Mr. Wallace were appointed to the Board, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Turner or Mr. Wallace that would be reportable under Item 404(a) of Regulation S-K.

Ms. Turner and Mr. Wallace will participate in the same compensation program as each of the Company’s other non-employee directors, as described under “Non-Employee Director Compensation” in the Company’s proxy statement for its 2023 annual meeting of shareholders filed with the Securities and Exchange Commission on April 6, 2023.

Item 7.01 Regulation FD Disclosure.

On April 1, 2024, the Company issued a press release announcing the appointment of Ms. Turner and Mr. Wallace to the Board and the Company’s entry into the Cooperation Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
10.1	Cooperation Agreement, dated as of March 29, 2024, by and among Elanco Animal Health Incorporated, Ancora Catalyst Institutional, LP and the other person and entities listed thereto.
99.1	Press Release issued by Elanco Animal Health Incorporated, dated as of April 1, 2024.
104.1	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Elanco Animal Health Incorporated
Date: April 1, 2024	By:	/s/ Shiv O’Neill
		Name:  Shiv O’Neill
		Title:  Executive Vice President, General Counsel and Corporate Secretary

EX-10.1

Exhibit 10.1

COOPERATION AGREEMENT

This Cooperation Agreement (this “Agreement”), dated as of March 29, 2024, is made by and among Elanco Animal Health Incorporated, an Indiana corporation (the “Corporation”), and the entities and natural persons set forth under the “Ancora Parties” caption in the signature pages hereto and their Affiliates or Associates (as such terms are defined below) (collectively, the “Ancora Parties” and individually a “Member” of the Ancora Parties) (the Corporation and the Ancora Parties together, collectively, the “Parties”).

WHEREAS, the Ancora Parties beneficially own an aggregate of 12,554,694 shares of common stock, no par value (the “Common Stock”), of the Corporation issued and outstanding on the date hereof;

WHEREAS, the Ancora Parties and the Corporation have engaged in discussions concerning the Board of Directors of the Corporation (the “Board”);

WHEREAS, on February 12, 2024, Ancora Catalyst Institutional, LP submitted a letter to the Corporation (the “Nomination Notice”) nominating certain director candidates to be elected to the Board at the 2024 annual Shareholder Meeting (as defined below); and

WHEREAS, the Parties have determined that it is in their respective best interests to come to an agreement with respect to the composition of the Board and certain other matters, as provided in this Agreement.

NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

1. Board Matters.

a. The Corporation shall, effective immediately following the execution and delivery of this Agreement, appoint Craig S. Wallace and Kathy V. Turner (collectively, the “New Independent Directors,” and individually a “New Independent Director”) to serve as directors of the Corporation, each with a term expiring at the 2025 annual Shareholder Meeting (it being understood that, as a matter of mechanics in order to comply with applicable law and the Corporation’s organizational documents, given the current allocation of directors across classes and the requirement to have the three classes be as nearly equal in number as possible, Ms. Turner will initially be appointed to the 2026 class and then ultimately be a member of, and be appointed to, the 2025 class in connection with the classes being rebalanced by the Board re-allocating an existing member of the 2025 class to the 2026 class, with such rebalancing occurring no later than completion of the 2024 annual Shareholder Meeting, and at least one of the Corporation’s incumbent directors who is serving as of the date hereof shall no longer serve as a member of the Board by the conclusion of the Corporation’s 2026 annual Shareholder Meeting).

b. The Corporation will include the New Independent Directors in the Corporation’s proxy statement for the 2024 annual Shareholder Meeting.

c. While each New Independent Director (and any Replacement Director, as applicable) serves as a director of the Board, he or she shall receive compensation (including equity-based compensation, if any), an annual retainer, and benefits (including expense reimbursements) on the same basis as all other non-employee directors of the Corporation as determined by the Board.

d. Concurrent with the execution of this Agreement, the Ancora Parties hereby (i) irrevocably withdraw the Nomination Notice and (ii) irrevocably withdraw any related materials or notices, including the letter dated February 29, 2024, demanding, pursuant to Chapter 52 Section 2 (IC 23-1-52-2) of the Indiana Business Corporation Law (the “IBCL”), to inspect certain books, records and documents of the Corporation and to make and/or receive copies or extracts therefrom.

e. The New Independent Directors (and any Replacement Director, as applicable) will be subject to the same protections and obligations regarding confidentiality, conflicts of interest, related party transactions, fiduciary duties (as set forth under Indiana law), codes of conduct, trading and disclosure policies (including the Corporation’s insider trading policy), director resignation policy, stock ownership guidelines and other governance guidelines and policies of the Corporation as other directors, as amended from time to time (collectively, the “Corporation Policies”), and shall have the same rights and benefits, including with respect to insurance, indemnification, compensation and fees, as are applicable to all non-employee directors of the Corporation. The Corporation shall make available to the New Independent Directors (or any Replacement Director) copies of all Corporation Policies not publicly available on the Corporation’s website. At all times while a New Independent Director (or any Replacement Director, as applicable) is serving as a member of the Board, (i) such New Independent Director (or any Replacement Director, as applicable) shall not disclose any confidential information of the Corporation and/or its subsidiaries to (x) the Ancora Parties, any Member of the Ancora Parties or any “Affiliate” or “Associate” (for purposes of this Agreement, as each is defined in Rule 12b-2 promulgated by the Securities and Exchange Commission (the “SEC”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of each such Member of the Ancora Parties (collectively and individually, the “Ancora Affiliates”) or (y) any other Person not affiliated with the Corporation, including, without limitation, any competitor of the Corporation or any of its subsidiaries, (ii) each Member of the Ancora Parties shall not, and shall cause the Ancora Affiliates not to, seek to obtain confidential information of the Corporation and/or its subsidiaries from any New Independent Director (or any Replacement Director, as applicable).

f. Notwithstanding anything to the contrary in this Agreement, the rights and privileges set forth in this Agreement shall be personal to the Ancora Parties and may not be transferred or assigned to any individual, corporation, partnership, limited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature (each, a “Person”), except that the Ancora Parties shall be permitted to transfer or assign this Agreement to their respective controlled Affiliates, provided that any such transfer or assignment shall not relieve any transferring Ancora Party of its obligations under this Agreement.

-2-

g. For purposes of this Agreement, the term “Beneficially Own” or variations thereof shall have the meaning set forth in Rule 13d-3 promulgated under the Exchange Act.

h. Promptly following the execution and delivery of this Agreement, the Board and all applicable committees thereof will take such actions as are necessary to ensure that the New Independent Directors be appointed to the Finance and Oversight Committee of the Board, which shall be renamed the “Finance, Strategy and Oversight Committee.”

i. If, during the Standstill Period (as defined below), any New Independent Director resigns from the Board or is rendered unable (due to death or disability) to, or refuses to, serve on the Board for any reason, and at all times since the date of this Agreement and at such time the Ancora Parties Beneficially Own in the aggregate at least 1.5% of the Corporation’s then-outstanding Common Stock (the “Minimum Ownership Level”), then, so long as the Ancora Parties Beneficially Own in the aggregate at least the Minimum Ownership Level, the Ancora Parties shall identify a replacement (who shall qualify as “independent” pursuant to the listing standards of the New York Stock Exchange and the applicable rules and regulations of the SEC) to fill the resulting vacancy caused by such New Independent Director’s departure from the Board and any such person will be appointed to the Board within five business days following, and subject to, the good faith review and approval of such person (such approval not to be unreasonably conditioned, withheld or delayed) by the Board after the Corporate Governance Committee has made a recommendation to the Board on whether to approve any such person (any such replacement director, a “Replacement Director”); provided that a Replacement Director will not be any current or former Affiliate, Associate or employee of any of the Ancora Parties. Upon a Replacement Director’s appointment to the Board, such Replacement Director will be deemed to be a New Independent Director for all purposes under this Agreement.

j. Each New Independent Director (or any Replacement Director, as applicable) shall have the same right as other members of the Board to be invited to attend meetings of committees of the Board of which any New Independent Director (or any Replacement Director, as applicable) is not a member. Furthermore, in addition to the Board committee appointments contemplated in Section 1(h), each New Independent Director (or any Replacement Director, as applicable) shall be considered for membership on other current committees of the Board (and any new committee(s), as applicable) in the same manner as other independent members of the Board. The current committees of the Board are the Audit Committee, Compensation and Human Capital Committee, the Corporate Governance Committee, the Finance and Oversight Committee and the Innovation, Science and Technology Committee.

-3-

2. Standstill and Voting.

a. The Ancora Parties each agree that during the Standstill Period (as defined below), the Ancora Parties and the Ancora Affiliates will not (and they will not assist or encourage others to), directly or indirectly, in any manner, without prior written approval of the Board:

i. take any actions, including acquiring, seeking to acquire or agreeing to acquire (directly or indirectly), whether by market purchases, private purchases, tender or exchange offer, through the acquisition of control of another person, by joining a “group” (within the meaning of Section 13(d)(3) of the Exchange Act), through swap or hedging transactions or otherwise, any shares of Common Stock (or Beneficial Ownership thereof) or any securities convertible or exchangeable into or exercisable for any shares of Common Stock (or Beneficial Ownership thereof) (including any derivative securities or any other rights decoupled from the underlying securities of the Corporation) such that the Ancora Parties would Beneficially Own in excess of 7.5% of the shares of Common Stock outstanding at such time;

ii. other than in open market sale transactions where the identity of the purchaser is not known, sell, offer, or agree to sell, directly or indirectly, through swap or hedging transactions or otherwise, the securities of the Corporation or any rights decoupled from the underlying securities held by the Ancora Parties to any person or entity not (A) a party to this Agreement, (B) a member of the Board, (C) an officer of the Corporation or (D) an Affiliate of the Ancora Parties (any person or entity not set forth in the foregoing clauses (A)-(D) shall be referred to as a “Third Party”) that would result in such Third Party, together with its Affiliates, owning, controlling or otherwise having any beneficial or other ownership interest representing in the aggregate in excess of 2.0% of the shares of Common Stock outstanding at such time;

iii. (A) advise or knowingly encourage or influence any other Person or knowingly assist any third party in so encouraging, assisting or influencing any other Person with respect to the giving or withholding of any proxy, consent or other authority to vote or in conducting any type of referendum (other than such encouragement, advice or influence that is consistent with the Board’s recommendation in connection with such matter) or (B) advise, influence or encourage any Person with respect to, or effect or seek to effect, whether alone or in concert with others, the election, nomination or removal of a director;

-4-

iv. solicit proxies or written consents of shareholders or conduct any other type of referendum (binding or non-binding) (including any “withhold,” “vote no” or similar campaign) with respect to the shares of Common Stock, or from the holders of the shares of Common Stock, or become a “participant” (as such term is defined in Instruction 3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in or knowingly encourage or assist any third party in any “solicitation” of any proxy, consent or other authority (as such terms are defined under the Exchange Act) to vote any shares of Common Stock (other than any encouragement, advice or influence that is consistent with the Board’s recommendation in connection with such matter);

v. (A) form, join or in any other way participate in a “group” with respect to any securities (other than a “group” solely consisting of the Ancora Parties or Ancora controlled Affiliates), (B) grant any proxy, consent or other authority to vote with respect to any matters to be voted on by the Corporation’s shareholders at any annual or special shareholder meeting or pursuant to an action by written consent of the shareholders (each a “Shareholder Meeting”), other than to the named proxies included in the Corporation’s proxy card for any Shareholder Meeting or in accordance with Section 2(b) or (C) agree to deposit or deposit any securities or any securities convertible or exchangeable into or exercisable for any such securities in any voting trust, agreement or similar arrangement (other than (I) to the named proxies included in the Corporation’s proxy card for any Shareholder Meeting, (II) customary brokerage accounts, margin accounts, prime brokerage accounts and the like or (III) any agreement solely among the Ancora Parties or Ancora controlled Affiliates);

vi. separately or in conjunction with any third party in which it is or proposes to be either a principal, partner or financing source or is acting or proposes to act as broker or agent for compensation, propose (publicly or privately, with or without conditions), indicate an interest in or effect any tender offer or exchange offer, merger, acquisition, division, reorganization, restructuring, recapitalization or other business combination involving the Corporation or any of its subsidiaries or the assets or businesses of the Corporation or any of its subsidiaries or actively encourage or initiate or support any other third party in any such activity; provided, however, that the Ancora Parties and Ancora Affiliates shall be permitted to (A) sell or tender their securities subject to applicable rules of the SEC and the New York Stock Exchange, and otherwise receive consideration, pursuant to any such transaction and (B) vote on any such transaction in accordance with Section 2(b);

vii. (A) nominate, recommend for nomination, or give notice of an intent to nominate or recommend for nomination a person for election at any Shareholder Meeting at which the Corporation’s directors are to be elected, (B) present at any Shareholder Meeting any proposal for consideration for action by the shareholders, or (C) call or seek to call, or request the call of, alone or in concert with others, or support another shareholder’s call for, any meeting of shareholders, whether or not such a meeting is permitted by the Corporation’s organizational documents;

-5-

viii. take any action in support of or make any proposal or request that constitutes: (A) controlling, changing or influencing the Board, management or policies of the Corporation, including any plans or proposals to change the number or term of directors or the removal of any directors, or to fill any vacancies on the Board; (B) any material change in the capitalization, stock repurchase programs and practices or dividend policy of the Corporation; (C) any other material change in the Corporation’s management, business or corporate structure; (D) seeking to have the Corporation waive or make amendments or modifications to the Corporation’s charter or bylaws or take other actions that may impede or facilitate the acquisition of control of the Corporation by any Person; (E) causing a class of securities of the Corporation to be delisted from, or to cease to be authorized to be quoted on, any securities exchange; or (F) causing a class of securities of the Corporation to become eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act, in each case with respect to the foregoing clauses (A) through (F);

ix. make any request for shareholder list materials or other books and records of the Corporation under Chapter 52 Section 2 (IC 23-1-52-2) of the IBCL, or otherwise; provided that if any New Independent Director (or any Replacement Director, as applicable) makes such a request solely in such New Independent Director’s (or any Replacement Director’s, as applicable) capacity as a director in a manner consistent with his or her fiduciary duties to the Corporation, such material and other books and records may not be shared with any other Ancora Party, Member of the Ancora Parties or any Ancora Affiliate, notwithstanding any other provision of this Agreement;

x. encourage, facilitate, support, participate in or enter into any negotiations, agreements, arrangements or understandings with respect to the taking of any actions by any other Person in connection with the foregoing that is prohibited to be taken by the Ancora Parties; or

xi. request that the Corporation, directly or indirectly, amend or waive any provision of this Section 2 (including this clause (a)(xi)), other than through non-public communications with the Corporation that would not reasonably be expected to trigger public disclosure obligations for any Party.

-6-

The foregoing provisions of this Section 2(a) shall not be deemed to prevent any Member of the Ancora Parties from (i) communicating privately with the Board or any of the Corporation’s executive officers regarding any matter, so long as such communications are not intended to, and would not reasonably be expected to, require the Corporation or any Member of the Ancora Parties to make public disclosure with respect thereto; (ii) communicating privately with shareholders of the Corporation and others in a manner that does not otherwise violate this Section 2(a), Section 3 hereof or any other provision of this Agreement; (iii) only during the period thirty (30) days prior to the termination of the Standstill Period, identifying potential director candidates to serve on the Board, so long as such actions do not create a public disclosure obligation for the Ancora Parties or the Corporation, are not publicly disclosed by the Ancora Parties or its Affiliates and are undertaken on a basis reasonably designed to be confidential; (iv) making or sending private communications to investors in any Member of the Ancora Parties or any of their Affiliates, provided that such statements or communications (1) are based on publicly available information, (2) are not reasonably expected to be publicly disclosed and are understood by all parties to be confidential communications, and (3) pertain to the investor’s investment in the Ancora Parties or any of their Affiliates; or (v) taking any action to the extent necessary to comply with any law, rule or regulation or any action required by any governmental or regulatory authority or stock exchange that has, or may have, jurisdiction over any Member of the Ancora Parties. Furthermore, for the avoidance of doubt, nothing in this Agreement shall be deemed to restrict in any way any New Independent Director (or any Replacement Director, as applicable) in the exercise of his or her fiduciary duties under applicable law as a director of the Corporation.

b. In respect of any vote or consent of the Corporation’s shareholders during the Standstill Period (whether at an annual or special shareholder meeting or pursuant to an action by written consent of the shareholders), the Ancora Parties and the Members of the Ancora Parties shall appear or act in person or by proxy and vote all shares of Common Stock Beneficially Owned by them in accordance with the recommendation of the Board with respect to (i) the election, removal and/or replacement of directors (a “Director Proposal”), (ii) the ratification of the appointment of the Corporation’s independent registered public accounting firm and (iii) any other proposal submitted to the Corporation’s shareholders at a Shareholder Meeting, in each case as such recommendation of the Board is set forth in the applicable definitive proxy statement filed in respect thereof; provided, however, that in the event Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co., LLC (“Glass Lewis”) make a recommendation that differs from the recommendation of the Board with respect to any proposal submitted to the shareholders at any Shareholder Meeting (other than Director Proposals), the Ancora Parties and the Members of the Ancora Parties are permitted to vote the shares of Common Stock Beneficially Owned by them at such Shareholder Meeting in accordance with the ISS or Glass Lewis recommendation; provided, further, that the Ancora Parties and the Members of the Ancora Parties shall be entitled to vote the shares of Common Stock Beneficially Owned by them in their sole discretion with respect (A) to any publicly announced proposal relating to any transaction pursuant to which any person is or becomes a Beneficial Owner, directly or indirectly, of securities of the Corporation representing more than 50% of the Corporation’s then outstanding equity interest and voting power, a merger, stock for stock transaction, acquisition, disposition of all or substantially all of the assets of the Corporation and its subsidiaries or other business combination involving the Corporation or (B) any financing, recapitalization, restructuring, share issuance or similar extraordinary transaction, in each case, that requires a vote of the Corporation’s shareholders.

c. The “Standstill Period” shall begin as of the date of this Agreement and shall remain in full force and effect until the earlier of (i) the date that is 30 days prior to the deadline for the submission of shareholder nominations for the 2025 annual Shareholder Meeting pursuant to the Corporation’s Amended and Restated Bylaws or (ii) the date that is 120 days prior to the first anniversary of the 2024 annual Shareholder Meeting, unless this Agreement is earlier terminated pursuant to Section 16.

-7-

d. Each Ancora Party shall comply, and shall cause each of its respective Ancora Affiliates to comply, with the terms of this Agreement and shall be responsible for any breach of this Agreement by any such Ancora Affiliate.

3. Mutual Non-Disparagement. During the Standstill Period, (a) the Ancora Parties shall not make, and shall cause their respective directors, officers, partners, members, employees, agents (in each case, acting in such capacity) and Affiliates not to make, or cause to be made, by press release or other public statement to the press or media (including social media), any statement or announcement that constitutes an ad hominem attack on, or otherwise disparages or damages, the Corporation, its subsidiaries or their respective officers and directors or any person who has served as an officer or director of the Corporation or any of its subsidiaries in the past, and (b) the Corporation shall not, and shall cause its directors and executive officers not to make, or cause to be made, by press release or other public statement to the press or media (including social media), any statement or announcement that constitutes an ad hominem attack on, or otherwise disparages or damages, the Ancora Parties, the Members of the Ancora Parties or their respective officers or directors or any person who has served as an officer or director of an Ancora Party in the past. The foregoing shall not prevent the making of any factual statement, including in any compelled testimony or production of information, either by legal process, subpoena, or as part of a response to a request for information from any governmental authority with purported jurisdiction over the party from whom information is sought.

4. Director Information. As a condition to each New Independent Director’s (or any Replacement Director’s, as applicable) nomination to serve on the Board and any subsequent nomination for election as a director at an annual meeting of the Corporation’s shareholders, such New Independent Director (or any Replacement Director, as applicable) will provide any information the Corporation reasonably requires, including information required by the Corporation’s Amended and Restated Bylaws, as then in effect, or to be disclosed in a proxy statement or other filing under applicable law, stock exchange rules or listing standards, information in connection with assessing eligibility, independence and other criteria applicable to directors or satisfying compliance and legal obligations, and will consent to appropriate background checks, to the extent, in each case, consistent with the information and background checks required by the Corporation in accordance with past practice with respect to other members of the Board. If, at any time following the completion of the Corporation’s background review process, the Board learns that any New Independent Director or any Replacement Director has committed, been indicted or charged with, or made a plea of nolo contendre to, a felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, then the Board may request that such New Independent Director (or any Replacement Director, as applicable) resign from the Board.

-8-

5. Disclosure of this Agreement. The Parties agree that, promptly following the execution of this Agreement, the Corporation will issue a press release (the “Press Release”) announcing this Agreement, substantially in the form attached hereto as Exhibit A. Prior to the issuance of the Press Release, neither the Corporation nor the Ancora Parties shall issue any press release or public announcement regarding this Agreement or take any action that would require public disclosure thereof without the prior written consent of the other Party. No Party or any of its Affiliates shall make any public statement (including, without limitation, in any filing required under the Exchange Act) concerning the subject matter of this Agreement inconsistent with the Press Release. During the period commencing on the date hereof and ending on the date this Agreement terminates in accordance with Section 16, no Party shall make any public announcement or statement that is inconsistent with or contrary to the statements made in the Press Release, except to the extent required by law or the rules and regulations under any stock exchange or governmental entity with the prior written consent of the Ancora Parties and the Corporation, as applicable, and otherwise in accordance with this Agreement. Notwithstanding the foregoing, the Ancora Parties acknowledge and agree that the Corporation may file this Agreement as an exhibit to a Current Report on Form 8-K within four (4) business days of the execution of this Agreement; provided that the Company shall first preview such Current Report with the Ancora Parties in advance of making such filing and consider reasonable comments by the Ancora Parties.

6. Expenses. No later than ten (10) business days following the execution of this Agreement, the Corporation shall reimburse the Ancora Parties for the reasonable, documented, out-of-pocket fees and expenses (including legal expenses) incurred as of or prior to the date hereof by the Ancora Parties in connection with their engagement with the Corporation, the negotiation and execution of this Agreement, and related matters, provided that such reimbursement shall not exceed $450,000 in the aggregate.

7. Representations and Warranties.

a. The Corporation represents and warrants to the Ancora Parties that: (i) the Corporation has the requisite corporate power and authority to execute this Agreement and any other documents or agreements to be entered into in connection with this Agreement and to bind it hereto and thereto; (ii) this Agreement has been duly and validly authorized, executed and delivered by the Corporation, constitutes a valid and binding obligation and agreement of the Corporation and is enforceable against the Corporation in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles; and (iii) the execution, delivery and performance of this Agreement by the Corporation does not and will not (x) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the Corporation or (y) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which the Corporation is a party or by which it is bound.

-9-

b. Each such Member of the Ancora Parties represents and warrants to the Corporation that: (a)(i) as of the date of this Agreement, each such Member of the Ancora Parties Beneficially Own, directly or indirectly, only the number of Common Stock as described opposite its name on Schedule A to this Agreement and such schedule includes all Affiliates of each such Member of the Ancora Parties that own any securities of the Corporation Beneficially or of record and reflects all Common Stock in which each such Member of the Ancora Parties has any interest or right to acquire, whether through derivative securities, voting agreements or otherwise; (a)(ii) as of the date of this Agreement, other than as disclosed herein, each such Member of the Ancora Parties does not currently have, and does not currently have any right to acquire, any interest in any other securities of the Corporation (or any rights, options or other securities convertible into or exercisable or exchangeable (whether or not convertible, exercisable or exchangeable immediately or only after the passage of time or the occurrence of a specified event) for such securities or any obligations measured by the price or value of any securities of the Corporation or any of its controlled Affiliates, including any swaps or other derivative arrangements designed to produce economic benefits and risks that correspond to the ownership of Common Stock, whether or not any of the foregoing would give rise to Beneficial Ownership (as determined under Rule 13d-3 promulgated under the Exchange Act), and whether or not to be settled by delivery of Common Stock, payment of cash or by other consideration, and without regard to any short position under any such contract or arrangement); (b) this Agreement has been duly and validly authorized, executed and delivered by each such Member of the Ancora Parties, and constitutes a valid and binding obligation and agreement of each such Member of the Ancora Parties, enforceable against each such Member of the Ancora Parties in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles; (c) each such Member of the Ancora Parties has the authority to execute this Agreement on behalf of itself and the applicable member of the Ancora Parties associated with that signatory’s name, and to bind each such Member of the Ancora Parties to the terms of this Agreement, including by virtue of having sole voting and dispositive power over each such Member of the Ancora Parties’ Common Stock; (d) each member of the Ancora Parties shall cause each of its respective Affiliates to comply with the terms of this Agreement, and (e) the execution, delivery and performance of this Agreement by each such Member of the Ancora Parties does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it or the New Independent Directors, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which each such Member of the Ancora Parties is a party or by which it is bound.  Each such Member of the Ancora Parties represents and warrants that it has no voting commitments (written or oral) with any of the New Independent Directors as of the date of this Agreement and agrees that it shall not compensate or otherwise incentivize any of the New Independent Directors for their service or action on the Board or enter into voting commitments, (written or oral) relating to the Corporation with any director or officer of the Corporation.  Except as otherwise disclosed in the Nomination Notice, each such Member of the Ancora Parties further represents and warrants that it does not have, directly or indirectly, any agreements, arrangements or understandings with any person (other than their own representatives) with respect to its investment in the Corporation, any strategic, capital, management or other operational matter with respect to the Corporation, any potential transaction involving the Corporation, or the acquisition, voting or disposition of any securities of the Corporation. Each such Member of the Ancora Parties further represents and warrants that no Member of the Ancora Parties has any control or influence over any compensation or other monetary payments to be received by any of the New Independent Directors in connection with their service as a director of the Corporation and that none of the Members of the Ancora Parties are aware of any facts or circumstances that will prevent any of the New Independent Directors from exercising independent judgment with respect to any matter involving the Corporation or items that may come before the Board or any of its committees.  Each such Member of the Ancora Parties further represents and warrants that the information previously provided to the Corporation is true, accurate and complete in all material respects.

-10-

8. Authority. The Ancora Parties hereby appoint Frederick DiSanto as the sole Member entitled to exercise the collective rights and remedies of the Ancora Parties hereunder, which appointee may be changed from time to time upon written notice to and approval from the Corporation (such approval not to be unreasonably withheld or delayed).

9. Amendment in Writing. This Agreement and each of its terms may only be amended, waived, supplemented or modified in a writing signed by the Parties hereto.

10. Governing Law/Venue/Waiver of Jury Trial/Jurisdiction. Each of the Parties (a) irrevocably and unconditionally consents to submit itself to the exclusive personal jurisdiction and venue of the United States District Court, Southern District of Indiana or the Marion Superior Court, Commercial Court Division, Marion County, Indiana in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (b) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (c) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the United States District Court, Southern District of Indiana or the Marion Superior Court, Commercial Court Division, Marion County, Indiana, and each of the Parties irrevocably waives the right to trial by jury, (d) agrees to waive any bonding requirement under any applicable law, in the case any other Party seeks to enforce the terms by way of equitable relief, and (e) irrevocably consents to service of process by a reputable overnight delivery service, signature requested, to the address of such Party’s principal place of business or as otherwise provided by applicable law. For the avoidance of doubt, the IBCL shall govern in all respects any matters related to this Agreement. FURTHER TO SUCH MATTERS, THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS, INCLUDING WITHOUT LIMITATION VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF INDIANA APPLICABLE TO CONTRACTS EXECUTED AND TO BE PERFORMED WHOLLY WITHIN SUCH STATE WITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE.

-11-

11. Specific Performance. The Parties expressly agree that an actual or threatened breach of this Agreement by any Party will give rise to irreparable injury that cannot adequately be compensated by damages. Accordingly, in addition to any other remedy to which it may be entitled, each Party shall be entitled to a temporary restraining order or injunctive relief to prevent a breach of the provisions of this Agreement or to secure specific enforcement of its terms and provisions, and each Party agrees it will not take any action, directly or indirectly, in opposition to another Party seeking relief. Each of the Parties agrees to waive any requirement for the security or posting of any bond in connection with any such relief.

12. Severability. If at any time subsequent to the date hereof, any provision of this Agreement shall be held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have no effect upon the legality or enforceability of any other provision of this Agreement.

13. Non-Waiver. No failure or delay by a Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or privilege hereunder.

14. Entire Agreement. This Agreement constitutes the full, complete and entire understanding, agreement, and arrangement of and between the Parties with respect to the subject matter hereof and supersedes any and all prior oral and written understandings, agreements and arrangements between them. There are no other agreements, covenants, promises or arrangements between the Parties other than those set forth in this Agreement (including the attachments hereto).

15. Notice. All notices and other communications which are required or permitted hereunder shall be in writing and shall be deemed validly given, made or served, when delivered in person or sent by overnight courier, when actually received during normal business hours, or on the date of dispatch by the sender thereof when sent by e-mail (to the extent that no “bounce back,” “out of office” or similar message indicating non-delivery is received with respect thereto), if such dispatch is made by 5:00 p.m. New York City time on a business day or, if made after 5:00 p.m. New York City time on a business day, such notice or other communication shall be deemed to have been received on the next succeeding business day, at the address specified in this Section 15:

If to the Corporation:

Elanco Animal Health Incorporated
2500 Innovation Way

Greenfield, Indiana 46140

Attention: Shiv O’Neill

-12-

with a copy, which will not constitute notice, to:

Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, New York 10019

Attention:	Daniel A. Neff Elina Tetelbaum
Email:	DANeff@wlrk.com ETetelbaum@wlrk.com

If to the Ancora Parties:

Ancora Holdings Group LLC
6060 Parkland Boulevard, Suite 200
Cleveland, Ohio 44124

Attention:	Jim Chadwick
Email:	jchadwick@ancora.net

with a copy, which will not constitute notice, to:

Wilson Sonsini Goodrich & Rosati
1301 Avenue of the Americas
New York, New York 10019

Attention:	Sebastian Alsheimer
Email:	salsheimer@wsgr.com

16. Termination. This Agreement shall cease, terminate and have no further force and effect upon the expiration of the last day of the Standstill Period as set forth in Section 2(c), unless earlier terminated by mutual written agreement of the Parties; provided that Sections 9 through 21 shall survive the termination of this Agreement.

17. Further Assurances. The Ancora Parties and the Corporation agree to take, or cause to be taken, all such further or other actions as shall reasonably be necessary to make effective and consummate the transactions contemplated by this Agreement.

18. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties named herein and their respective successors and permitted assigns. No Party may assign or otherwise transfer either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other Parties; provided, however, that the Ancora Parties may assign this Agreement to the extent set forth in Section 1(f). Any purported transfer requiring consent without such consent shall be void.

19. No Third-Party Beneficiaries. This Agreement is solely for the benefit of the Parties and is not enforceable by any other Person.

-13-

20. Interpretation; Construction. Each of the Parties acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed this Agreement with the advice of such counsel. Each Party and its counsel cooperated and participated in the drafting and preparation of this Agreement, and any and all drafts relating thereto exchanged among the Parties shall be deemed the work product of all of the Parties and may not be construed against any Party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any Party that drafted or prepared it is of no application and is hereby expressly waived by each of the Parties, and any controversy over interpretations of this Agreement shall be decided without regard to events of drafting or preparation. When a reference is made in this Agreement to a Section or Clause, such reference shall be to a Section or Clause of this Agreement, unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” and “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word “will” shall be construed to have the same meaning as the word “shall.” The words “date hereof” will refer to the date of this Agreement. The word “or” is not exclusive. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement, instrument, law, rule or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule or statute as from time to time amended, modified or supplemented.

21. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

[The remainder of this page is left blank intentionally.]

-14-

IN WITNESS WHEREOF, the Parties hereto have each executed this Agreement on the date first set forth above.

THE CORPORATION:
ELANCO ANIMAL HEALTH INCORPORATED
By:	/s/ Shiv O’Neill
	Name:	Shiv O’Neill
	Title:	Executive Vice President, General Counsel, and Corporate Secretary

[Signature page to the Cooperation Agreement]

THE ANCORA PARTIES:

Ancora Catalyst Institutional, LP

Ancora Catalyst, LP

Ancora Merlin Institutional, LP

Ancora Merlin, LP

Ancora Bellator Fund, LP

Ancora Impact Fund LP Series Z

Ancora Alternatives SMAs

By:	Ancora Alternatives LLC,
	its Investment Adviser and General Partner

By:	Ancora Holdings Group, LLC,
	its Sole Member

By:	/s/ Frederick D. DiSanto
Name: Frederick D. DiSanto
Title: Chairman and Chief Executive Officer
Ancora Alternatives LLC

By: Ancora Holdings Group, LLC, its Sole Member

By:	/s/ Frederick D. DiSanto
Name: Frederick D. DiSanto
Title: Chairman and Chief Executive Officer
Ancora Holdings Group, LLC
By:	/s/ Frederick D. DiSanto
Name: Frederick D. DiSanto
Title: Chairman and Chief Executive Officer
/s/ Frederick D. DiSanto
Frederick D. DiSanto

[Signature page to the Cooperation Agreement]

EXHIBIT A

Press Release

**Included as Exhibit 99.1 to this Current Report on Form 8-K**

SCHEDULE A

THE ANCORA PARTIES

Investor Name	Beneficial Ownership
Ancora Catalyst Institutional, LP	Ancora Catalyst Institutional, LP beneficially owns directly 2,210,442 shares of Common Stock (including (i) 100 shares held in record name and (ii) 301,200 shares of Common Stock underlying 3,012 American call options).
Ancora Catalyst, LP	Ancora Catalyst, LP beneficially owns directly 231,470 shares of Common Stock (including the 31,900 shares of Common Stock underlying 319 American call options).
Ancora Merlin Institutional, LP	Ancora Merlin Institutional, LP Institutional beneficially owns directly 2,213,380 shares of Common Stock (including the 305,300 shares of Common Stock underlying 3,053 American call options).
Ancora Merlin, LP	Ancora Merlin, LP beneficially owns directly 207,463 shares of Common Stock (including the 28,000 shares of Common Stock underlying 280 American call options)
Ancora Bellator Fund, LP	Ancora Bellator Fund, LP beneficially owns directly 644,412 shares of Common Stock (including the 133,300 shares of Common Stock underlying 1,333 American call options)
Ancora Impact Fund LP Series Z	Ancora Impact Fund LP Series Z beneficially owns directly 4,757,777 shares of Common Stock (including 308,800 shares of Common Stock underlying 3,088 American call options).
Ancora Alternatives SMAs	Ancora Alternatives SMAs collectively beneficially owns directly 2,289,750 shares of Common Stock (including the 805,000 shares of Common Stock underlying 8,050 American call options, consisting of shares of Common Stock held in certain separately managed accounts, collectively, the “Ancora Alternatives SMAs”).
Ancora Alternatives LLC	As the general partner and investment manager of each of Ancora Catalyst Institutional, LP, Ancora Catalyst, LP, Ancora Merlin Institutional, LP, Ancora Merlin, LP, Ancora Bellator Fund, LP and Ancora Impact Fund LP Series Z (collectively, the “Ancora Funds”), Ancora Alternatives LLC may be deemed to beneficially own the 12,554,694 shares of Common Stock beneficially owned in the aggregate by the Ancora Funds and held in the Ancora Alternatives SMAs (including the 1,913,500 shares of Common Stock underlying 19,135 American call options).
Ancora Holdings Group, LLC	As the sole member of Ancora Alternatives LLC, Ancora Holdings Group, LLC may be deemed to beneficially own the 12,554,694 shares of Common Stock beneficially owned in the aggregate by the Ancora Funds and held in the Ancora Alternatives SMAs (including the 1,913,500 shares of Common Stock underlying 19,135 American call options).

Investor Name	Beneficial Ownership
Frederick D. DiSanto	As the Chairman and Chief Executive Officer of Ancora Holdings Group, LLC, Mr. DiSanto may be deemed to beneficially own the 12,554,694 shares of Common Stock beneficially owned in the aggregate by the Ancora Funds and held in the Ancora Alternatives SMAs (including the 1,913,500 shares of Common Stock underlying 19,135 American call options).

EX-99.1

Exhibit 99.1

	Elanco Animal Health
	2500 Innovation Way
	Greenfield, IN 46140

FOR IMMEDIATE RELEASE 

Investor Contact: Kathryn Grissom, +1.317.273.9284, kathryn.grissom@elancoah.com

Media Contact: Colleen Parr Dekker, +1.317.989.7011, colleen.dekker@elancoah.com

Joele Frank: Kelly Sullivan / Adam Pollack (212) 355-4449

Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

New Directors Join the Board’s Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora

GREENFIELD, Ind. (DATE) – Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the “Board”), effective immediately, expanding the Board to 14 members.

Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Laboratories, including most recently as Chief Marketing Officer, and served in various roles of increasing responsibility at Abbott Laboratories. Mr. Wallace is a well-respected animal health leader with more than 30 years of executive experience at companies such as Fort Dodge Animal Health, Trupanion and Ceva.

Elanco Chairman R. David Hoover said, “We are pleased to have reached an agreement with Ancora on a constructive path forward, and we look forward to working with Kathy and Craig toward our common goal of progressing our robust and innovative pipeline and driving near- and long-term sustainable growth and value for our shareholders.”

Ms. Turner and Mr. Wallace also joined the Board’s Finance, Strategy and Oversight Committee, which has been renamed to better reflect its charter and mandate.

“We are pleased to welcome Kathy and Craig, both accomplished animal health industry executives, to the Elanco Board," said Jeff Simmons, President and CEO of Elanco Animal Health. “We are making meaningful progress as we continue to execute our Innovation, Portfolio and Productivity strategy, and we are confident that Kathy and Craig will be valuable additions to the Board.”

Frederick DiSanto, Chairman and Chief Executive Officer of Ancora Holdings Group LLC, added: “After recent engagement with Elanco, we have aligned on a constructive agreement that adds two pet healthcare experts to the Board and one of its key committees focused on strategic planning. Craig and Kathy are proven industry operators with experience that can support ongoing efforts to advance the high-quality pipeline assembled by management. Our recent interactions with Elanco give us confidence that Jeff and the Board are focused on the right steps with respect to corporate governance and value creation.”

In connection with today’s announcement, the Company has entered into a Cooperation Agreement with Ancora Holdings Group LLC and its affiliates that contains customary standstill, voting and other provisions. The agreement will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.

About Kathy Turner 

Kathy Turner held senior leadership positions in international commercial operations at IDEXX Laboratories (NASDAQ: IDXX), a global pet healthcare innovation company, from 2014 to 2023, including most recently serving as Chief Marketing Officer. She brings deep understanding of veterinary clinic operations through her tenure with IDEXX. In her nearly 30-year tenure at Abbott Laboratories (NYSE: ABT), a multinational medical devices and healthcare company, she held multiple leadership positions, most recently leading commercial operations for Europe. She is currently on the Board of Veterinarians Without Borders, an organization that promotes animal well-being, human health and economic development domestically and internationally.

About Craig Wallace 

Craig Wallace is President of C.S. Wallace Investments & Strategy, LLC, an animal health and human healthcare investment firm. Mr. Wallace previously served as Chief Executive Officer (North America/Pacific) of Ceva Santé Animale, the fifth largest animal health company worldwide. He also held leadership roles at Trupanion, Inc. (NASDAQ: TRUP), a pet insurance provider, and Fort Dodge Animal Health, a global manufacturer of animal health products for the livestock, companion animal, equine, swine and poultry industries. Additionally, he served on various boards of directors including the National Commission on Veterinary Economic Issues and the Kansas City Animal Health Corridor Advisory Board. He currently serves on the Board of Directors of 1C, a pet retail distributor, and KeraVet Bio, a veterinary wound care company.

About Elanco 

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability Initiatives – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning future business activities and financial performance, and may be identified by the use of words like “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “project,” “consider,” “predict,” “potential,” “feel,” or other comparable terminology. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include but are not limited to the following: operating in a highly competitive industry; the success of our research and development (R&D) and licensing efforts; the impact of disruptive innovations; competition from generic products; an outbreak of infectious disease carried by farm animals; risks related to the evaluation of animals; consolidation of our customers and distributors; the impact of increased or decreased sales into our distribution channels; our dependence on the success of our top products; our ability to complete acquisitions and divestitures and successfully integrate the businesses we acquire, including the proposed divestiture of our aqua business; our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements; manufacturing problems and capacity imbalances; fluctuations in inventory levels in our distribution channels; ; the impact of weather conditions, including those related to climate change, and the availability of natural resources; the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern; the loss of key personnel or highly skilled employees; adverse effects of labor disputes, strikes and/or work stoppages; the effect of our substantial indebtedness on our business; changes in interest rates; risks related to the write-down of goodwill or identifiable intangible assets; the lack of availability or significant increases in the cost of raw materials; risks related to our presence in foreign markets; risks related to currency rate fluctuations; risks related to underfunded pension plan liabilities; the potential impact that actions by activist shareholders could have on the pursuit of our business strategies; risks related to certain governance provisions in our constituent documents; actions by regulatory bodies, including as a result of their interpretation of studies on product safety; the possible slowing or cessation of acceptance and/or adoption of our farm animal sustainability initiatives; the impact of increased regulation or decreased governmental financial support related to the raising, processing or consumption of farm animals; the impact of litigation, regulatory investigations, and other legal matters, including the risk to our reputation; challenges to our intellectual property rights or our alleged violation of rights of others; misuse, off-label or counterfeiting use of our products; unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products. For additional information about these and other factors that could cause actual results to differ materially from forward-looking statements, please see the Risk Factors in the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

# # #

XML

Cover	Mar. 29, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 29, 2024
Entity File Number	001-38661
Entity Registrant Name	Elanco Animal Health Incorporated
Entity Central Index Key	0001739104
Entity Tax Identification Number	82-5497352
Entity Incorporation, State or Country Code	IN
Entity Address, Address Line One	2500 Innovation Way
Entity Address, City or Town	Greenfield
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46140
City Area Code	877
Local Phone Number	352-6261
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	ELAN
Security Exchange Name	NYSE
Entity Emerging Growth Company	false